Magic mushrooms offer much more than a psychedelic afternoon. They offer legitimate health benefits — backed up through large-scale clinical trials and decades’ worth of research.
Research began back in the 1960s. Right away, research started showing improvements in psychiatric conditions such as schizophrenia, depression, addiction, and existential anxiety.
Today, research on magic mushrooms and other psychedelics is at its prime — there are dozens of studies published on the therapeutic applications every year.
Benefits of magic mushrooms that have been confirmed through medical research:
- Alleviates or prevents cluster headaches & migraines
- Reduces cravings & addiction to drugs, alcohol, & cigarettes
- Supports creative thought & focus (microdoses)
- Alleviate existential dread & anxiety
- Improve symptoms of PTSD, generalized anxiety, & social anxiety disorders
- Improves chronic depression & other mood disorders
- Alleviates symptoms of obsessive-compulsive disorder (OCD)
Outside of these benefits, there are a lot of anecdotal reports on the use of magic mushrooms for other conditions and applications as well.
Benefits that have not yet been confirmed through research:
- Alleviates symptoms of ADD & ADHD
- Alleviates migraine headaches
- Reduces symptoms associated with premenstrual syndrome
- May relieve shingles pain
Magic Mushrooms for Cluster Headaches
A cluster headache is similar to a migraine but differentiates in its frequency and duration. Cluster headaches come and go several times throughout the day; each experience lasting 15 minutes to 2 hours at a time. Migraines tend to last much longer and only come on once per day or less.
Cluster headaches can cause significant amounts of pain. One of the common names for this condition is “suicide headaches” because the pain is so great it can leave sufferers contemplating suicide at times.
Research on the effects of psilocybin on cluster headaches is still in its infancy — but the results published so far are very promising.
The team at Clusterbusters.org published the results of a survey they sent out to their readers in 2015. This project was formed after the founders discovered evidence that compounds like LSD had the potential to treat cluster headaches — a condition with a notoriously poor prognosis for treatment.
The results of this study were based on the self-reported data of 496 cluster-headaches sufferers (diagnosis confirmed by neurologist).
The study reported that psilocybin from magic mushrooms was the most effective for preventing cluster headache attacks overall (33.7%).
This was followed by the pharmaceutical medication verapamil (16.6%), LSA (16.1%), steroids (15.1%), LSD (6.5%), and vitamins (3.5%).
Magic Mushrooms for Depression
One of the most promising therapeutic benefits of magic mushrooms is in the treatment of chronic depression.
A study published by the Beckley Foundation involving 12 patients with severe treatment-resistant depression gave patients either 10 or 25 mg of pure psilocybin to explore the impact on symptoms. The study noted a significant reduction in depression scores following the study, which remained intact six months later during a follow-up examination.
There are two methods of using magic mushrooms for the purposes of managing depression:
- Microdoses taken over long periods of time
- One or two sessions of a psychoactive dose
One of the ways psilocybin is thought to work for depression comes down to its effects on the 5HT serotonin receptors. Psilocybin has been shown to interact with the 5-HT1A, 5-HT1D, 5-HT2A, and 5-HT2C receptors — several of which are the targets for common antidepressant medications (SSRIs).
For microdosing, the idea is that steady, consistent doses of psilocybin have a downregulating effect on the serotonin receptors over time. Studies have shown that increased binding activity at the serotonin receptors (primarily 5-HT2A) plays a role in depression.
For microdosing (psychedelic experience), a similar effect on the serotonin receptors is taking place here as well, but there’s another layer to the benefits.
Psychedelics like psilocybin, LSD, LSA, DMT, and mescaline are all thought to “reset” a system in the brain called the default mode network (DMN) — which we’ll explore in more detail below.
The DMN is involved with our image of self and self-worth — and thought to play a major role in the development of depression. Brain imaging studies have shown psilocybin is able to “reset” and “restructure” the DMN in a way that makes the mind less susceptible to depression and anxiety .
Magic Mushrooms for Anxiety
Studies involving the use of psilocybin-containing mushrooms have been ongoing since the 1960s. There have also been thousands of anecdotal reports of users eliminating or dramatically reducing their anxiety symptoms with the help of psychoactive mushrooms over the past 60 years.
More recently, there have been a couple of high-profile clinical studies on the use of magic mushrooms (and related indoleamine compounds) for the treatment of anxiety disorders.
In 2011, a study explored the effects of psilocybin on terminally ill cancer patients diagnosed with acute stress disorder, generalized anxiety disorder, or adjustment disorder with anxiety (as per the DSM-IV protocol) .
Each patient had two sessions — one with 0.2 mg/kg psilocybin, the other with a placebo (niacin) — each session was several months apart.
This study found that the psilocybin dose resulted in a significant reduction in anxiety scores in the majority of patients — which were sustained at the 6-month follow-up period.
Another study (2016) compared the impact of microdosing magic mushrooms versus psychoactive dosing on cancer patients diagnosed with both depression and anxiety. This study noted that psychoactive doses had a much greater improvement in depression and anxiety scores than the microdose group.
The only problem with this study is that researchers failed to test the long-term impact of microdosing. Most experts agree, the benefits of microdosing stem from long-term, ongoing use rather than a one-off treatment.
Magic Mushrooms For Addiction
Most of the research on the use of psychedelics for treating addiction revolves around LSD (older research focus) or ayahuasca (newer research focus). Magic mushrooms are often grouped under these studies because of their ability to interact with the same receptors — the 5HT2A serotonin receptors.
A study published in 2015 explored the impact of psilocybin in the treatment of alcohol addiction. This study involved two sessions involving doses of either 0.3 or 0.4 mg/kg of pure psilocybin (equivalent to around 4 or 6 grams of magic mushrooms).
Following the treatment, researchers reported a dramatic down-tick in alcohol consumption and cravings among the study participants that were maintained at the conclusion of the follow-up period 36 weeks later.
Another study looked at the impact of psilocybin on another common addiction — tobacco . This study gave patients a dose of either 20 or 30 mg of pure psilocybin per 70 kg of body weight (equivalent to around 3.5 – 5 grams of dried mushrooms).
At the conclusion of this study, researchers reported an incredible 80% of patients were able to quit smoking by the end of the six-month study period. To put this into perspective, the standard interventions involving pharmaceutical medications have an average quit-rat of just 35%.
Magic Mushrooms Microdosing For Focus, Concentration, & Creativity
This practice became famous after it came to light that many of the successful CEOs and executives working for tech companies in Silicon Valley were using microdosing to be more efficient with their work.
There has yet to be any official studies exploring this effect, but a company called MindMed is currently recruiting for a phase II clinical trial to explore a similar compound — LSD — to assess its effects on focus and concentration.
A man named Dr. James Fadiman has been collecting informal data on this effect for the past couple of years, which he recently published in a paperback in 2019 . His study aimed to create a protocol for microdosing magic mushrooms and LSD to eliminate some of the variables with user reporting. He then asked users to submit their anecdotal reports after following his protocol.